ReviewPharmacogenomics and personalized medicine2016
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Review in Pharmacogenomics and personalized medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Single-cell transcriptional atlas of human breast cancers and model systems.Clinical and translational medicine · 2024Article
- Core Needle Biopsy Guidance Based on Tissue Morphology Assessment with AI-OCT Imaging.Diagnostics (Basel, Switzerland) · 2023Article
- Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status.Scientific reports · 2023Article
- Early Diagnosis and Real-Time Monitoring of Regional Lung Function Changes to Prevent Chronic Obstructive Pulmonary Disease Progression to Severe Emphysema.Journal of clinical medicine · 2021Review
- Recommendations for streamlining precision medicine in breast cancer care in Latin America.Cancer reports (Hoboken, N.J.) · 2021Review
- Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs.Nature communications · 2021Article
- Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.International journal of molecular sciences · 2019Article
- Clinical target sequencing for precision medicine of breast cancer.International journal of clinical oncology · 2019Review
- Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer.PloS one · 2019Article
- A molecular multi-gene classifier for disease diagnostics.Nature chemistry · 2018Article
- Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.ACS nano · 2018Review
- Article
- Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches.Journal of molecular biomarkers & diagnosis · 2017Article
- Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions.The oncologist · 2017Review
- Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Journal of clinical pharmacology · 2016Review
- Precision medicine in cardiology.Nature reviews. Cardiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2. Lately, there has been a surge in the development, commercialization, and marketing of diagnostic assays to assist in breast cancer patient care. More recently, multigene signature assays, such as Oncotype DX, MammaPrint, and Prosigna, have been integrated in the clinical setting in order to tailor decisions on adjuvant endocrine and chemotherapy treatment. This review provides an overview of the current state of breast cancer management and the use of companion diagnostics to direct personalized approaches in the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.